Biotech Archives - Page 671 of 795

1 minute read

Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids

October 5, 1:31 PM

The FDA has accepted Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) supplemental marketing application for the potential expanded use of TAKHZYRO (lanadelumab-flyo) for…

TAK

1 minute read

Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer’s Trial

By Vandana Singh

October 5, 12:45 PM

Alzamend Neuro Inc (NASDAQ:ALZN) has dosed its first healthy adult subject in its Phase 2A multiple ascending dose (MAD) study of…

ALZN

1 minute read

Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study

By Vandana Singh

October 5, 11:20 AM

Eliem Therapeutics Inc (NASDAQ:ELYM) announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and…

ELYM

1 minute read

Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment

By Vandana Singh

October 5, 9:50 AM

Following FDA feedback, Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) will not submit an emergency use authorization (EUA) application of peginterferon lambda for mild-to-moderate COVID-19.…

EIGR

5 minute read

FDA
News

AnaptysBio And GSK-Partnered Immuno-Oncology Agents JEMPERLI (dostarlimab-gxly) And Cobolimab Show Progress In Two Separate Non-small Cell Lung Cancer Trials

By Benzinga Newsdesk

October 5, 9:02 AM

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials Positive headline results from PERLA, a head-to

ANAB

4 minute read

Acer Therapeutics Announces Expansion Of ACER-801 Development Indications To Include Post-Traumatic Stress Disorder

By Benzinga Newsdesk

October 5, 8:32 AM

Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a

ACER

1 minute read

Leap Therapeutics To Present Updated Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Preclinical Data In Colorectal Cancer Models At The Society of Immunotherapy for Cancer Annual Meeting

By Benzinga Newsdesk

October 5, 8:19 AM

CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be

LPTX

2 minute read

Ikena Oncology To Present Initial Phase 1a/b Results From Novel AHR Inhibition Program At The 2022 Society For Immunotherapy Of Cancer 37th Annual Meeting

By Benzinga Newsdesk

October 5, 8:17 AM

Ikena Oncology, Inc. (NASDAQ:IKNA, ", Ikena", )))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl

IKNA

1 minute read

AbCellera Announces Presentation Of Data From CD3 T-Cell Engager Platform At Society for Immunotherapy of Cancer November 11 2022

By Benzinga Newsdesk

October 5, 8:11 AM

AbCellera (NASDAQ:ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8

ABCL

4 minute read

Aytu BioPharma Announces Continuing Availability Of ADHD Medication Adzenys XR-ODT(R) In Response To Reported Generic Adderall(R) XR Supply Disruptions

By Benzinga Newsdesk

October 5, 8:05 AM

Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset

AYTU